Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung

A southwest oncology group study

Stephen K. Williaon, John J. Crowley, Robert B. Livingston, Timothy Panella, John Wendall Goodwin

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background Fazarabine is a novel nucleoside with broad spectrum pre-clinical activity and was chosen for study in patients with incurable non-small cell carcinoma of the lung. The expenses associated with investigational treatment have been assumed to be more than what would occur with conventional therapy, however, data are limited. Methods Twently-three patients with metastatic non-small cell lung cancer were treated with fazarabine. Fazarabine was administered as a 72 hour continuous infusion, at 2.0 mg/M2/hour. A cost analysis of treatment was calculated for patients treated in Springfield, MO. Results There were no responses (0%, 95% confidence interval=0–15%) and median survival was 8 months. An analysis of the cost of treatment in the 4 patients treated in Springfield, MO, was compared to the costs of treatment with 4 cycles of cisplatinum and etoposide. There were no significant differences in costs for patients treated with the investigational agent as compared with conventional chemotherapy. Conclusions Fazarabine has no demonstrable activity in patients with metastatic non-small cell carcinoma of the lung. Treatment with this agent in an investigational setting was no more expensive than treatment with conventional chemotherapy.

Original languageEnglish (US)
Pages (from-to)67-71
Number of pages5
JournalInvestigational New Drugs: An Interdisciplinary Journal for Clinicians and Scientists
Volume13
Issue number1
DOIs
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

fazarabine
Non-Small Cell Lung Carcinoma
Costs and Cost Analysis
Health Care Costs
Drug Therapy
Investigational Therapies
Etoposide
Therapeutics
Nucleosides
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung : A southwest oncology group study. / Williaon, Stephen K.; Crowley, John J.; Livingston, Robert B.; Panella, Timothy; Goodwin, John Wendall.

In: Investigational New Drugs: An Interdisciplinary Journal for Clinicians and Scientists, Vol. 13, No. 1, 01.01.1995, p. 67-71.

Research output: Contribution to journalArticle

@article{c4beb9b9bfc4479a888c9af1d7ba2574,
title = "Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A southwest oncology group study",
abstract = "Background Fazarabine is a novel nucleoside with broad spectrum pre-clinical activity and was chosen for study in patients with incurable non-small cell carcinoma of the lung. The expenses associated with investigational treatment have been assumed to be more than what would occur with conventional therapy, however, data are limited. Methods Twently-three patients with metastatic non-small cell lung cancer were treated with fazarabine. Fazarabine was administered as a 72 hour continuous infusion, at 2.0 mg/M2/hour. A cost analysis of treatment was calculated for patients treated in Springfield, MO. Results There were no responses (0{\%}, 95{\%} confidence interval=0–15{\%}) and median survival was 8 months. An analysis of the cost of treatment in the 4 patients treated in Springfield, MO, was compared to the costs of treatment with 4 cycles of cisplatinum and etoposide. There were no significant differences in costs for patients treated with the investigational agent as compared with conventional chemotherapy. Conclusions Fazarabine has no demonstrable activity in patients with metastatic non-small cell carcinoma of the lung. Treatment with this agent in an investigational setting was no more expensive than treatment with conventional chemotherapy.",
author = "Williaon, {Stephen K.} and Crowley, {John J.} and Livingston, {Robert B.} and Timothy Panella and Goodwin, {John Wendall}",
year = "1995",
month = "1",
day = "1",
doi = "10.1007/BF02614223",
language = "English (US)",
volume = "13",
pages = "67--71",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung

T2 - A southwest oncology group study

AU - Williaon, Stephen K.

AU - Crowley, John J.

AU - Livingston, Robert B.

AU - Panella, Timothy

AU - Goodwin, John Wendall

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Background Fazarabine is a novel nucleoside with broad spectrum pre-clinical activity and was chosen for study in patients with incurable non-small cell carcinoma of the lung. The expenses associated with investigational treatment have been assumed to be more than what would occur with conventional therapy, however, data are limited. Methods Twently-three patients with metastatic non-small cell lung cancer were treated with fazarabine. Fazarabine was administered as a 72 hour continuous infusion, at 2.0 mg/M2/hour. A cost analysis of treatment was calculated for patients treated in Springfield, MO. Results There were no responses (0%, 95% confidence interval=0–15%) and median survival was 8 months. An analysis of the cost of treatment in the 4 patients treated in Springfield, MO, was compared to the costs of treatment with 4 cycles of cisplatinum and etoposide. There were no significant differences in costs for patients treated with the investigational agent as compared with conventional chemotherapy. Conclusions Fazarabine has no demonstrable activity in patients with metastatic non-small cell carcinoma of the lung. Treatment with this agent in an investigational setting was no more expensive than treatment with conventional chemotherapy.

AB - Background Fazarabine is a novel nucleoside with broad spectrum pre-clinical activity and was chosen for study in patients with incurable non-small cell carcinoma of the lung. The expenses associated with investigational treatment have been assumed to be more than what would occur with conventional therapy, however, data are limited. Methods Twently-three patients with metastatic non-small cell lung cancer were treated with fazarabine. Fazarabine was administered as a 72 hour continuous infusion, at 2.0 mg/M2/hour. A cost analysis of treatment was calculated for patients treated in Springfield, MO. Results There were no responses (0%, 95% confidence interval=0–15%) and median survival was 8 months. An analysis of the cost of treatment in the 4 patients treated in Springfield, MO, was compared to the costs of treatment with 4 cycles of cisplatinum and etoposide. There were no significant differences in costs for patients treated with the investigational agent as compared with conventional chemotherapy. Conclusions Fazarabine has no demonstrable activity in patients with metastatic non-small cell carcinoma of the lung. Treatment with this agent in an investigational setting was no more expensive than treatment with conventional chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0029157676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029157676&partnerID=8YFLogxK

U2 - 10.1007/BF02614223

DO - 10.1007/BF02614223

M3 - Article

VL - 13

SP - 67

EP - 71

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -